At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 101 enrolled

Drug / intervention

PF-06863135 monotherapy IV or SC +3 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03269136

NCT03269136Phase 1Completed

Compare CT.gov

MAGNETISMM-1 A PHASE I, OPEN LABEL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETIC, PHARMACODYNAMIC AND CLINICAL ACTIVITY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) - CD3 BISPECIFIC ANTIBODY, AS A SINGLE AGENT AND IN COMBINATION WITH IMMUNOMODULATORY AGENTS IN PATIENTS WITH RELAPSED/REFRACTORY ADVANCED MULTIPLE MYELOMA (MM)

Pfizer·interventional·Posted Aug 31, 2017·Updated Mar 18, 2025

In Brief

A Phase 1 clinical trial evaluating PF-06863135 monotherapy IV or SC, PF-06863135 + dexamethasone, and 2 other interventions for Multiple Myeloma. Completed, enrolled 101 participants across 37 sites in 2 countries.

Detailed Summary

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsMultiple Myeloma

CountriesCanada, United States

Collaborators--

Timeline

Phase 1CompletedFinished

201820192020202120222023202420252026

First PostedAug 2017

Enrollment StartNov 2017

Primary CompletionJan 2024

TodayJul 2026

First PostedAug 31, 2017

Enrollment StartNov 29, 2017

Primary CompletionJan 19, 2024

TodayJul 2, 2026

Enrollment to primary: 6.1 yearsPosted 8.8 years ago

Interventions

PF-06863135 monotherapy IV or SCdrug

PF-06863135 will be administered intravenously or subcutaneously.

PF-06863135 + dexamethasonedrug

PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.

PF-06863135 + lenalidomidedrug

PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally

PF-06863135 + pomalidomidedrug

PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally